Goldline Pharmaceutical IPO is a book-built issue IPO, aiming to raise ₹11.61 crore. The issue is entirely a fresh issue of 27.00 lakh equity shares aggregating to ₹11.61 crore. The bidding window opened on May 12, 2026, and closed on May 14, 2026, with the IPO allotment expected to be finalised on May 15, 2026. Goldline Pharmaceutical is scheduled to list on the BSE SME platform on May 19, 2026.
The IPO was priced at ₹41-₹43 per share with a lot size of 3,000 shares. The public issue received a strong response from investors, achieving an overall subscription of 840.74 times. Non-Institutional Investors led the response by subscribing 1662.04 times their quota, followed by Retail Individual Investors at 881.15 times and Qualified Institutional Buyers at 180.21 times.
Goldline Pharmaceutical’s ₹11.61 crore IPO, priced at ₹41-₹43 per share, was subscribed 840.74 times overall. The IPO consists entirely of a fresh issue of 27.00 lakh equity shares aggregating to ₹11.61 crore.
Bidding took place from May 12 to May 14, 2026, with the Goldline Pharmaceutical IPO allotment status expected on May 15, 2026. Retail investors subscribed 881.15 times, while NIIs subscribed 1662.04 times. Listing is expected on May 19, 2026, on the BSE SME platform.
The table below breaks down the Goldline Pharmaceutical IPO share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| QIB Shares Offered | 1272000 |
| − Anchor Investor Shares Offered | 732000 |
| − QIB (Ex. Anchor) Shares Offered | 540000 |
| NII (HNI) Shares Offered | 390000 |
| − bNII > ₹10L | 258000 |
| − sNII < ₹10L | 132000 |
| Retail Shares Offered | 900000 |
| Firm Reservations | |
| Market Maker Shares Offered | 138000 |
| Total Shares Offered | 2700000 |
Data Source: BSE
| Category | Subscription (times) |
| Qualified Institutional Buyers | 180.21 |
| Non-Institutional Investors | 1662.04 |
| Retail Individual Investors | 881.15 |
| Total Shares | 840.74 |
Note: The subscription details are as of May 14, 2026
Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi.
Goldline Pharmaceuticals is engaged in the marketing of pharmaceutical products under the “Goldline” brand. The company operates through an asset-light business model and partners with third-party manufacturers for product manufacturing based on its specifications and market research. This allows the company to focus on branding, distribution, and market expansion while maintaining quality and regulatory compliance.
The company’s product portfolio is divided into 5 key segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These divisions cater to multiple therapeutic specialities including cardiology, diabetology, orthopaedics, ENT, gastroenterology, neurology, paediatrics, critical care, oncology support, and general medicine. Through this diversified portfolio, the company addresses a broad range of healthcare requirements across speciality and general medical practices.
Goldline Pharmaceutical markets and sells all its products through a network of distributors supplying retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors while also supporting hospitals and healthcare providers with procurement and material supply services. Its products are sold across Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar, providing the company with a growing regional presence in the Indian pharmaceutical market.
The business is supported by experienced promoters and management personnel with industry knowledge and established supplier relationships. The company’s competitive strengths include its scalable business model, diverse product offerings, asset-light operations, and established distribution network. By leveraging partnerships with manufacturers and distributors, Goldline Pharmaceutical aims to strengthen its market position and continue expanding its product reach across various therapeutic categories.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 14, 2026, 6:01 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
